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B-Type Natriuretic Peptide in Patients With Acute Dyspnea
Andreas S. Pahlea,b, Daniel Sørlia,b, Torbjørn Omland, MD, PhD, MPHa,b,*,
Cathrine Wold Knudsen, MD, PhDc, Arne Westheim, MD, PhDd, Alan H.B. Wu, PhDe,
Philippe Gabriel Steg, MDf, James McCord, MDg, Richard M. Nowak, MD, MBAg,
Judd E. Hollander, MDh, Alan B. Storrow, MDi, William T. Abraham, MDj,
Peter A. McCullough, MD, MPHk, and Alan Maisel, MDl
Hypertension may affect the diagnostic performance of B-type natriuretic peptide (BNP).
The objective of the present study was to assess the impact of a history of hypertension or
blood pressure elevation on admission on the diagnostic performance of BNP in the
diagnosis of heart failure (HF) in patients with acute dyspnea. BNP levels were measured
using a rapid point-of-care device in 1,586 patients with acute dyspnea. In patients with
HF, BNP levels did not differ between those with and without histories of hypertension.
Conversely, in patients without HF, a history of hypertension was associated with higher
median BNP levels (38 pg/ml [interquartile range 13 to 119] vs 21 pg/ml [interquartile range
7 to 64], p <0.001). The areas under the receiver-operating characteristic curves were 0.88
and 0.93 for those with and without histories of hypertension, respectively (p <0.001).
Blood pressure elevation on admission did not affect the diagnostic accuracy of BNP (areas
under the curve 0.90 in the 2 groups). In conclusion, although a history of hypertension is
associated with higher BNP levels in patients with acute dyspnea without HF, the impact
on the overall diagnostic performance of BNP is modest. Accordingly, BNP performs well
as an indicator of HF in patients presenting in emergency departments regardless of a
history of hypertension or elevated blood pressure on admission. © 2009 Elsevier Inc. All
rights reserved. (Am J Cardiol 2009;104:966–971)
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dArterial hypertension and left ventricular hypertrophy
ave been associated with increased plasma B-type natri-
retic peptide (BNP) concentrations.1 A history of hyper-
ension could thus theoretically obscure the association be-
ween BNP and heart failure (HF) and reduce the diagnostic
erformance of BNP. Moreover, it is conceivable that acute
ressure overload, commonly seen in patients presenting
ith acute dyspnea, may cause acute BNP elevation. Ac-
ordingly, the objective of the present study was to inves-
igate whether a history of hypertension, or actual blood
ressure elevation on admission, affects the diagnostic per-
ormance of BNP as a diagnostic marker of HF in patients
ith acute dyspnea.
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The Breathing Not Properly Multinational Study was a
-center diagnostic test evaluation trial conducted from
pril 1999 to December 2000.2 The study’s main aim was
o evaluate the utility of BNP measurement for diagnosing
F in the emergency department. A total of 1,586 patients,
ll presenting with acute dyspnea in the emergency depart-
ent, were enrolled. Of the cohort, 99 patients had no
ecorded data of medical histories of hypertension, leaving
,487 patients for analysis of the effects of a history of
ypertension. Three patients did not have complete data for
lood pressure, leaving 1,583 in this subgroup. Patients
resenting with acute myocardial infarctions or renal failure
estimated creatinine clearance 15 ml/min and those re-
eiving dialysis therapy), those aged 18 years, those un-
ble to give informed consent, and those with dyspnea due
o obvious noncardiac origins (e.g., penetrating lung injury)
ere excluded. All patients were examined according to
ommon clinical practice by an emergency physician. This
ncluded a thorough medical history and physical examina-
ion. A research assistant collected the patients’ electrocar-
iograms, laboratory test results, and current medication
nformation. Blood samples for subsequent BNP analysis
ere collected before the initiation of medical therapy.
The diagnosis of (1) dyspnea due to acute HF, (2) a history
f HF but current dyspnea due to a noncardiac cause, or (3)
yspnea due to a noncardiac cause was made by 2 experienced
ardiologists at each center. For the purposes of this study, the
www.AJConline.org
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967Heart Failure/Hypertension and Diagnostic Performance of BNPlatter groups were pooled. The 2 cardiologists were blinded
o the BNP results. Because not all patients underwent the
ame battery of diagnostic tests, no formal criteria for the
iagnosis of HF were used by the 2 cardiologists. To classify
atients into 1 of the 3 categories, the cardiologists did, how-
ver, have access to the emergency department sheets and
nformation obtained after the initial assessment in the emer-
ency department. This could include chest x-ray, reported by
radiologist; additional medical history; and echocardio-
raphic reports or radionuclide or contrast ventriculographic
eports. Echocardiography was performed in 709 of 1,586
atients, of whom 492 were diagnosed with HF. Echocardio-
raphic examinations were performed according to the local
ractices of the participating academic centers (i.e., without
ormalization of echocardiographic methods across centers).
ecause the HF category could include patients with systolic
F and those with nonsystolic HF, no specific value for the left
entricular ejection fraction was used to distinguish patients
ith and without final diagnoses of HF. The 2 cardiologists
ere also presented with calculated Framingham scores for
ongestive HF and the National Health and Nutrition Exami-
ation Survey (NHANES) congestive HF scores. These calcu-
ations were based on case reports. For the non-HF group,
onfirmation of the diagnosis was based on normal chest x-ray
ndings (i.e., absence of radiographic cardiomegaly); evident
hronic obstructive pulmonary disease, pneumonia, trauma, or
ung cancer; and normal heart function assessed by echocar-
iography, radionuclide ventriculography, or contrast ventricu-
ography. The most common causes of acute dyspnea in pa-
ients without HF or with histories of HF were chronic
able 1
atient characteristics according to history of hypertension status
ariable
N
(n 
inal diagnosis of heart failure 210 (34
ge (years) 61 (45
en 362 (60
revious heart failure 139 (22
revious myocardial infarction 114 (19
iabetes mellitus 73 (12
trial fibrillation/flutter 57 (9.4
ody mass index (kg/m2) 25.4 (22
ystolic blood pressure (mm Hg) 130 (11
iastolic blood pressure (mm Hg) 75 (66
ean arterial pressure (mm Hg) 93.3 (83
eart rate (beats/min) 91 (80
reatinine (mg/dl) 1.0 (0.8
NP 100 pg/ml 268 (44
NP (pg/ml) 66.6 (14
edications at home
Angiotensin-converting enzyme inhibitors 110 (18
 blockers 84 (14
Calcium channel blockers 60 (10
Digoxin 86 (14
Other antiarrhythmic agents 29 (4.9
Diuretics 199 (33
Data are expressed as number (percentage) or as median (IQR).bstructive pulmonary disease, asthma, pneumonia, and ane- tia. The 2 cardiologists agreed initially in their assessments in
,420 of 1,586 patients.
The study protocol was approved by the institutional
eview boards of all participating hospitals. Written in-
ormed consent was obtained from all participants. The
tudy adhered to the principles outlined in the Declaration
f Helsinki. All procedures followed were in accordance
ith institutional guidelines.
Five milliliters of venous blood was collected from each
atient into ethylenediaminetetraacetic acid Vacutainer tubes
Becton, Dickinson & Company, Franklin Lakes, New Jersey).
NP concentrations were measured using the Triage BNP
est (Biosite Diagnostics, Inc., San Diego, California). The
haracteristics of this sandwich fluorescence immunoassay
or the rapid quantitative determination of BNP in whole
lood and plasma have been described previously.2–4 Three
onsecutive BNP tests were performed, and the mean of
hese is presented.
The Breathing Not Properly study protocol did not spec-
fy a formal procedure for blood pressure recording. Ac-
ordingly, blood pressure was measured according to the
outine procedures of the emergency departments of the
articipating centers. Absolute blood pressure values were
sed, and no rounding to 0 or 5 was performed.
A history of hypertension was ascertained by interviewing
ach patient. This study used the European Hypertension So-
iety’s5 definition of hypertension: systolic blood pressure
140 mm Hg and/or diastolic blood pressure 90 mm Hg.
he acute setting of the Breathing Not Properly study did not
trictly fulfill the criteria for diagnosing hypertension.5 We
History of Hypertension p Value
Yes
(n  879)
477 (54.3%) 0.001
68 (56–77) 0.001
475 (54.0%) 0.038
364 (41.4%) 0.001
248 (31.1%) 0.001
280 (34.1%) 0.001
88 (10.0%) 0.723
) 28.1 (24.2–33.5) 0.001
147 (128–165) 0.001
80 (68–93) 0.001
102.7 (89.3–115.7) 0.001
88 (74–103) 0.001
1.1 (0.8–1.4) 0.001
558 (63.5%) 0.001
3) 253.7 (45.8–795.7) 0.001
348 (40.9%) 0.001
234 (27.7%) 0.001
259 (30.7%) 0.001
173 (20.3%) 0.005
66 (7.8%) 0.031
496 (57.9%) 0.001o
608)
.5%)
–75)
.0%)
.9%)
.2%)
.1%)
%)
.3–30.4
4–147)
–85)
–105)
–109)
–1.2)
.1%)
.2–358.
.5%)
.1%)
.1%)
.5%)
%)
.3%)herefore use the term “elevated blood pressure” in this report.
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968 The American Journal of Cardiology (www.AJConline.org)hus, the following subgroups were defined: (1) self-reported
istory of hypertension versus no history of hypertension and
2) elevated versus no elevated blood pressure on admission.
SPSS for Windows version 16.0 (SPSS, Inc., Chicago,
llinois) was used for all statistical analyses. Continuous
ata are presented as median (interquartile range [IQR]) and
ategorical data as percentages. Between-group differences
ere assessed using the Mann-Whitney U test and the
hi-square test or Fisher’s exact test, as appropriate, for
ontinuous and categorical data, respectively. Spearman’s
ank correlations and linear regression analyses were used
o assess relations between continuous variables. A 2-sided
value 0.05 was considered significant.
Sensitivity, specificity, accuracy, positive and negative pre-
ictive values, and positive and negative likelihood ratios for
he detection of acute HF were calculated. Receiver-operating
haracteristic (ROC) curves were generated and used to assess
he overall diagnostic accuracy of BNP. The areas under the
OC curves were calculated with 95% confidence intervals
CIs), and the optimal discriminatory cut-off value was esti-
ated using MedCalc version 9.5.2.0. Comparisons of 2 areas
nder ROC curves were conducted in MedCalc with reference
o the algorithms of Hanley and McNeil.6
esults
Patient characteristics according to the presence or ab-
ence of a history of hypertension are listed in Table 1, and
atient characteristics according to the presence or absence
f elevated blood pressure on admission are listed in Table
. Median circulating BNP levels were significantly higher
n patients with versus without histories of hypertension
254 pg/ml [IQR 46 to 796] vs 67 pg/ml [IQR 14 to 358],
0.001). However, this could be attributed mainly to a
igher prevalence of a final diagnosis of HF in the patients
ith histories of hypertension (54% vs 35%, p 0.001).
In patients with HF, median BNP levels did not differ
ignificantly between those with and those without histories
f hypertension (599 pg/ml [IQR 287 to 1,178] vs 562 pg/ml
230 to 1,121], p  0.34). In patients without HF, median
irculating levels of BNP were significantly higher in those
ith histories of hypertension than in those without such
istories (38 pg/ml [IQR 13 to 119] vs 21 pg/ml [7 to 64],
0.001). Using BNP as the predictor variable and the
resence of acute HF as the outcome variable, the introduc-
ion of a history of hypertension and elevated blood pressure
n admission in logistic regression models only marginally
nfluenced the odds ratio estimates for BNP and the explan-
tory power of the models (data not shown). The association
etween a history of hypertension and BNP levels was
ttenuated but remained significant (p  0.017) after ad-
ustment for age, gender, and body mass index. Circulating
NP levels in patients with final diagnoses of HF or no HF
tratified according to the presence or absence of a history
f hypertension are depicted in Figure 1. To assess the
verall diagnostic performance of BNP in patients with and
ithout histories of hypertension, ROC analysis was per-
ormed. The area under the ROC curve for patients with
istories of hypertension was significantly lower than for
hose without such histories (0.88 [95% CI 0.85 to 0.90] vs
.93 [95% CI 0.91 to 0.95], p 0.001; Figure 2). The dptimal BNP cut-off points, as assessed by ROC analysis,
ere 194 and 115 pg/ml for patients with and without
istories of hypertension, respectively. Diagnostic accuracy
t different cut-off values of BNP is listed in Table 3.
Median circulating blood levels of BNP were signifi-
antly higher in patients with elevated blood pressure than
n those without elevated blood pressure (171 pg/ml [IQR
3 to 734] vs 131 pg/ml [IQR 21 to 588] pg/ml, p  0.012;
able 2). A final diagnosis of HF was significantly more
ommon (51% vs 42%, p  0.005) in those patients pre-
enting with elevated blood pressure than in those without
levated blood pressure. Circulating BNP levels in patients
ith final diagnoses of HF or no HF stratified according to
he presence or absence of elevated blood pressure on ad-
ission are depicted in Figure 3. In patients without HF, the
edian BNP level did not differ significantly between those
ith elevated blood pressure and those without elevated
lood pressure (32 vs 28 pg/ml, p  0.18). Likewise, in
atients with final diagnoses of HF, the median BNP level
able 2
atient characteristics according to the presence or absence of elevated
lood pressure* on admission
ariable Elevated Blood Pressure p
Value
No Yes
(n  740) (n  843)
inal diagnosis of heart
failure
314 (42.4%) 427 (50.7%) 0.005
ge (years) 64 (49–76) 67 (54–78) 0.001
en 444 (60.0%) 437 (51.8%) 0.001
revious heart failure 245 (33.1%) 281 (33.3%) 0.957
revious myocardial
infarction
193 (29.1%) 192 (25.1%) 0.094
ypertension 317 (45.9%) 562 (70.8%) 0.001
iabetes mellitus 175 (25.7%) 192 (25.3%) 0.856
trial fibrillation/flutter 125 (18.9%) 131 (17.1%) 0.407
ody mass index
(kg/m2)
26.1 (23–31) 27.8 (24–33) 0.001
ystolic blood pressure
(mm Hg)
120 (107–130) 156 (146–174) 0.001
iastolic blood pressure
(mm Hg)
68 (60–76) 89 (79–99) 0.001
ean arterial pressure
(mm Hg)
84.7 (77–93) 110 (103–121) 0.001
eart rate (beats/min) 90 (75–107) 90 (76–105) 0.752
reatinine (mg/dl) 1.0 (0.8–1.3) 1.0 (0.8–1.3) 0.230
NP 100 pg/ml 399 (53.9%) 497 (59.0%) 0.047
NP (pg/ml) 130.7 (21–588) 170.7 (33–734) 0.012
edications at home
Angiotensin-converting
enzyme inhibitors
219 (30.3%) 265 (32.7%) 0.322
 blockers 145 (20.1%) 197 (24.3%) 0.049
Calcium channel
blockers
137 (19.0%) 193 (23.9%) 0.021
Digoxin 157 (21.8%) 136 (16.6%) 0.011
Other antiarrhythmic
agents
58 (8.1%) 47 (5.9%) 0.105
Diuretics 340 (47.0%) 401 (48.9%) 0.475
Data are expressed as number (percentage) or as median (IQR).
* Systolic blood pressure 140 mm Hg and/or diastolic blood pressure
90 mm Hg.id not differ significantly between those with elevated
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969Heart Failure/Hypertension and Diagnostic Performance of BNPlood pressure and those without elevated blood pressure
616 vs 588 pg/ml, p  0.75). In accordance with these
esults, no correlation was observed between BNP levels
nd systolic (r  0.05, p  0.06) or diastolic (r  0.04, p 
.09) blood pressure. Moreover, the areas under the ROC
urves were nearly identical for the 2 groups (0.900 [95%
I 0.877 to 0.919] vs 0.897 [95% CI 0.873 to 0.918], p 
.89; Figure 4). Optimal cut-off points were estimated to be
50 and 205 pg/ml for those with and without elevated
lood pressure, respectively. Overall diagnostic accuracy
or the diagnosis HF at different cut-off values of BNP in
atients with and without elevated blood pressure on admis-
ion is listed in Table 4. In the 2 groups, accuracy reached
plateau between 100 and 200 pg/ml.
iscussion
The main findings of this study are that in patients with
cute dyspnea with HF, a history of hypertension does not
ffect BNP levels, whereas in patients without HF, a history
Figure 1. BNP levels in patients with dyspnea stratified according to final d
igure 2. Overall diagnostic accuracy of BNP according to the presence or
bsence of a history of hypertension.f hypertension is associated with higher BNP levels. The association between a history of hypertension and BNP
evels was attenuated but remained significant after adjust-
ent for age, gender, and body mass index. Although the
iagnostic accuracy of BNP was significantly lower in pa-
ients with histories of hypertension than in those without
uch histories, the difference was modest and due partly to
onfounding by age and gender. However, our results sug-
est that the optimal discriminatory BNP value for the
iagnosis of HF is slightly higher in patients with histories
f hypertension than for those without histories of hyper-
ension.
Long-standing hypertension is associated with hypertro-
hy, fibrosis, and eventually diastolic and systolic dysfunc-
ion of the left ventricle.7 Because the main stimulus for
NP production from cardiac ventricles and atria is wall
tretch,8 it is not surprising that a history of hypertension
nd left ventricular hypertrophy is associated with increased
NP levels in population-based studies.9 In addition, in-
reased left ventricular mass per se may contribute to in-
reased BNP levels.1 No previous study has examined the
ffect of a history of arterial hypertension or the effect of
levated blood pressure on the performance of BNP levels
n patients with acute dyspnea, a patient group in which
everal extracardiac and cardiac factors other than left ven-
ricular failure may cause elevated BNP levels10 and thus
heoretically obscure the association between hypertension
nd BNP levels. Our data demonstrate that a history of
ypertension is associated with modestly but significantly
ncreased circulating BNP levels in patients with acute dys-
nea without final diagnoses of HF. The presence of ele-
ated blood pressure on presentation did not affect BNP
evels, even in patients without final diagnoses of HF. The
ack of a correlation between BNP and blood pressure
alues supports the notion that actual blood pressure does
ot represent a major stimulus for BNP production. The
eason the effect of a history of hypertension was not de-
onstrable in patients with final diagnoses of HF can prob-
s and to the presence or absence of a history (Hx) of hypertension (HTN).bly be ascribed to the fact that left ventricular failure
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nosis and to the presence or absence of elevated blood pressure (BP) on admission.
970 The American Journal of Cardiology (www.AJConline.org)epresents a much stronger stimulus for BNP production,
hus obscuring the impact of hypertension.
In accordance with the observation that a history of
ypertension is associated with increased circulating BNP
evels in patients without final diagnoses of HF, the overall
iagnostic accuracy was slightly lower and the optimal
iagnostic cutoff defined by ROC analysis slightly higher in
atients with than in those without histories of hypertension.
owever, the clinical impact of the observation of a higher,
athematically derived cutoff in patients with histories of
ypertension is likely to be minor, because in the clinical
etting, higher sensitivity may be more desirable than mar-
inally better overall diagnostic accuracy. Accordingly, on
he basis of the present data, we that believe it is justified to
se the established BNP cutoff of 100 pg/ml for the diag-
osis of HF in patients with acute dyspnea, regardless of a
able 3
ecision statistics at different cut-off values for patients with and withou
NP Cutoff Sensitivity Specificity
istory of hypertension
50 0.97 0.56
100 0.9 0.72
120 0.88 0.76
140 0.86 0.78
160 0.85 0.8
180 0.83 0.83
200 0.82 0.85
300 0.74 0.88
o history of hypertension
50 0.98 0.7
100 0.9 0.83
120 0.87 0.85
140 0.83 0.88
160 0.82 0.89
180 0.8 0.92
200 0.79 0.93
300 0.68 0.95
Figure 3. BNP levels in patients with dyspnea stratified according final diagistory of hypertension or not. a Elevated blood pressure
 No elevated blood pressure
Se
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iti
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y
1-specificity
igure 4. Overall diagnostic accuracy of BNP according to the presence ort histories of hypertension
Positive Predictive Value Negative Predictive Value Accuracy
0.75 0.93 0.79
0.81 0.85 0.83
0.83 0.82 0.82
0.84 0.81 0.83
0.85 0.8 0.83
0.87 0.78 0.83
0.88 0.78 0.83
0.89 0.72 0.8
0.65 0.98 0.8
0.75 0.94 0.85
0.76 0.92 0.85
0.79 0.9 0.86
0.81 0.9 0.87
0.85 0.89 0.88
0.86 0.89 0.88bsence of elevated blood pressure on admission.
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971Heart Failure/Hypertension and Diagnostic Performance of BNPPotential limitations of our study are that no distinction
as made between systolic and diastolic HF and that a
istory of hypertension was either self-reported or based on
nformation from medical records.
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